Peter de Keizer → FOXO4-DRI
Peter de Keizer's senescent-cell research connects to FOXO4-DRI, a senolytic peptide that induces apoptosis in senescent cells by disrupting the FOXO4-p53 interaction, with mouse outcomes reported but his exact role and human safety and efficacy not established.
FOXO4-DRI is a cell-penetrating peptide that disrupts the interaction between two proteins, FOXO4 and p53. In a senescent cell, this disruption pushes p53 out of the nucleus and triggers apoptosis, the cell's built-in death program. The compound's defining property is selectivity: it targets senescent cells.
Peter de Keizer, Associate Professor at University Medical Center Utrecht (UMC Utrecht) and founder of Cleara Biotech, studies the heterogeneity of senescent cells and develops approaches to eliminate their harmful effects in aging and cancer. FOXO4-DRI targets the very senescent cells de Keizer works on. His exact role with the peptide (whether he discovered it, developed it, or only studied it) cannot be established from the available material.
In mouse studies, FOXO4-DRI restored tissue homeostasis after chemotoxic damage. In naturally aged and accelerated-aging mice, the treatment improved fitness, fur density, and kidney function. Effect sizes and experimental conditions are not given. The available data do not establish safety or efficacy in humans.
High-confidence edge (0.99) linking a named researcher to a concrete mechanistic compound; the dossier contains enough specific detail (protein interaction, apoptosis pathway, mouse phenotype outcomes) to explain both endpoints plainly and point readers toward what evidence remains unverified.